Nymox Pharmaceutical (Nasdaq: NYMX) announced that the Independent Data Monitoring Committee for the Company's Phase 2 study of NX-1207 for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE